Toward optimizing pomalidomide therapy in MM patients

Klaus Podar

doi:10.1182/blood-2015-05-641746

Toward optimizing pomalidomide therapy in MM patients

Klaus Podar

Publikation: Beitrag in Fachzeitschrift (peer-reviewed) › Artikel in Fachzeitschrift

1 Zitat (Scopus)

Abstract

In this issue of Blood, Sehgal et al report on the clinical and pharmacodynamic analysis of pomalidomide dosing strategies in multiple myeloma (MM) and their impact on immune activation and cereblon targets. The particular novelty of this study lies in the direct correlation of immune effects triggered by pomalidomide with clinical responses in MM patients. Results of this study will stimulate many additional studies.

Originalsprache	Englisch
Seiten (von - bis)	3968-3969
Seitenumfang	2
Fachzeitschrift	Blood
Jahrgang	125
Ausgabenummer	26
DOIs	https://doi.org/10.1182/blood-2015-05-641746
Publikationsstatus	Veröffentlicht - 25 Juni 2015
Extern publiziert	Ja

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

ASJC Scopus Sachgebiete

Biochemie
Immunologie
Hämatologie
Zellbiologie

Zugriff auf Dokument

10.1182/blood-2015-05-641746

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

@article{d908b1ec5e0a42c4b15a6a7beb25cc5b,

title = "Toward optimizing pomalidomide therapy in MM patients",

abstract = "In this issue of Blood, Sehgal et al report on the clinical and pharmacodynamic analysis of pomalidomide dosing strategies in multiple myeloma (MM) and their impact on immune activation and cereblon targets. The particular novelty of this study lies in the direct correlation of immune effects triggered by pomalidomide with clinical responses in MM patients. Results of this study will stimulate many additional studies.",

keywords = "Angiogenesis Inhibitors/therapeutic use, Female, Humans, Male, Multiple Myeloma/drug therapy, Thalidomide/analogs \& derivatives",

author = "Klaus Podar",

note = "Publisher Copyright: {\textcopyright} 2015 by The American Society of Hematology.",

year = "2015",

month = jun,

day = "25",

doi = "10.1182/blood-2015-05-641746",

language = "English",

volume = "125",

pages = "3968--3969",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "26",

}

TY - JOUR

T1 - Toward optimizing pomalidomide therapy in MM patients

AU - Podar, Klaus

PY - 2015/6/25

Y1 - 2015/6/25

N2 - In this issue of Blood, Sehgal et al report on the clinical and pharmacodynamic analysis of pomalidomide dosing strategies in multiple myeloma (MM) and their impact on immune activation and cereblon targets. The particular novelty of this study lies in the direct correlation of immune effects triggered by pomalidomide with clinical responses in MM patients. Results of this study will stimulate many additional studies.

AB - In this issue of Blood, Sehgal et al report on the clinical and pharmacodynamic analysis of pomalidomide dosing strategies in multiple myeloma (MM) and their impact on immune activation and cereblon targets. The particular novelty of this study lies in the direct correlation of immune effects triggered by pomalidomide with clinical responses in MM patients. Results of this study will stimulate many additional studies.

KW - Angiogenesis Inhibitors/therapeutic use

KW - Female

KW - Humans

KW - Male

KW - Multiple Myeloma/drug therapy

KW - Thalidomide/analogs & derivatives

UR - https://www.scopus.com/pages/publications/84933575811

U2 - 10.1182/blood-2015-05-641746

DO - 10.1182/blood-2015-05-641746

M3 - Journal article

C2 - 26113530

SN - 0006-4971

VL - 125

SP - 3968

EP - 3969

JO - Blood

JF - Blood

IS - 26

ER -

Toward optimizing pomalidomide therapy in MM patients

Abstract

UN SDGs

ASJC Scopus Sachgebiete

Zugriff auf Dokument

Andere Dateien und Links

Fingerprint

Dieses zitieren